CN113662970A - Application of umbilical cord stem cell preparation in preparation of osteoarthritis treatment drug - Google Patents
Application of umbilical cord stem cell preparation in preparation of osteoarthritis treatment drug Download PDFInfo
- Publication number
- CN113662970A CN113662970A CN202111005448.9A CN202111005448A CN113662970A CN 113662970 A CN113662970 A CN 113662970A CN 202111005448 A CN202111005448 A CN 202111005448A CN 113662970 A CN113662970 A CN 113662970A
- Authority
- CN
- China
- Prior art keywords
- umbilical cord
- tissue
- preparation
- culture
- stem cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000003954 umbilical cord Anatomy 0.000 title claims abstract description 94
- 238000002360 preparation method Methods 0.000 title claims abstract description 52
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 40
- 201000008482 osteoarthritis Diseases 0.000 title claims abstract description 26
- 239000003814 drug Substances 0.000 title claims abstract description 13
- 229940079593 drug Drugs 0.000 title description 5
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims abstract description 39
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 27
- DXDRHHKMWQZJHT-FPYGCLRLSA-N isoliquiritigenin Chemical compound C1=CC(O)=CC=C1\C=C\C(=O)C1=CC=C(O)C=C1O DXDRHHKMWQZJHT-FPYGCLRLSA-N 0.000 claims abstract description 19
- JBQATDIMBVLPRB-UHFFFAOYSA-N isoliquiritigenin Natural products OC1=CC(O)=CC=C1C1OC2=CC(O)=CC=C2C(=O)C1 JBQATDIMBVLPRB-UHFFFAOYSA-N 0.000 claims abstract description 19
- 235000008718 isoliquiritigenin Nutrition 0.000 claims abstract description 19
- 238000004519 manufacturing process Methods 0.000 claims abstract 2
- 235000015110 jellies Nutrition 0.000 claims description 22
- 239000008274 jelly Substances 0.000 claims description 22
- 102000004169 proteins and genes Human genes 0.000 claims description 14
- 239000002504 physiological saline solution Substances 0.000 claims description 11
- 239000006228 supernatant Substances 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 10
- 230000008569 process Effects 0.000 claims description 7
- 238000004115 adherent culture Methods 0.000 claims description 6
- 239000001963 growth medium Substances 0.000 claims description 6
- 210000004027 cell Anatomy 0.000 claims description 5
- 238000000108 ultra-filtration Methods 0.000 claims description 5
- 230000007910 cell fusion Effects 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 3
- 239000012634 fragment Substances 0.000 claims description 3
- 238000010008 shearing Methods 0.000 claims description 3
- 239000012879 subculture medium Substances 0.000 claims description 3
- 210000001612 chondrocyte Anatomy 0.000 abstract description 14
- 239000003550 marker Substances 0.000 abstract description 13
- 230000008439 repair process Effects 0.000 abstract description 5
- 206010061218 Inflammation Diseases 0.000 abstract description 4
- 230000004054 inflammatory process Effects 0.000 abstract description 4
- 230000000857 drug effect Effects 0.000 abstract description 2
- 210000001519 tissue Anatomy 0.000 description 48
- 230000006378 damage Effects 0.000 description 13
- 206010003246 arthritis Diseases 0.000 description 11
- 238000011552 rat model Methods 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 7
- 210000000629 knee joint Anatomy 0.000 description 7
- 230000001575 pathological effect Effects 0.000 description 7
- 238000010276 construction Methods 0.000 description 6
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000006285 cell suspension Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 238000005070 sampling Methods 0.000 description 4
- 241000700159 Rattus Species 0.000 description 3
- 210000001503 joint Anatomy 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 208000006820 Arthralgia Diseases 0.000 description 2
- 230000002917 arthritic effect Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000003321 cartilage cell Anatomy 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 102100022464 5'-nucleotidase Human genes 0.000 description 1
- 108010067219 Aggrecans Proteins 0.000 description 1
- 208000036487 Arthropathies Diseases 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 101150082216 COL2A1 gene Proteins 0.000 description 1
- 102100037241 Endoglin Human genes 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000881679 Homo sapiens Endoglin Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 1
- 206010023203 Joint destruction Diseases 0.000 description 1
- 206010023232 Joint swelling Diseases 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- JDNTWHVOXJZDSN-UHFFFAOYSA-N iodoacetic acid Chemical compound OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0668—Mesenchymal stem cells from other natural sources
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Hematology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Microbiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present disclosure relates to the use of an umbilical cord stem cell preparation in the manufacture of a medicament for the treatment of osteoarthritis, the umbilical cord stem cell preparation comprising: umbilical cord mesenchymal stem cells, a tissue extract and isoliquiritigenin. The umbilical cord stem cells can reduce inflammatory reaction to a certain extent, improve the expression of chondrocyte marker genes, and effectively improve the repair function of the umbilical cord stem cells by adding tissue extract, isoliquiritigenin and the umbilical cord stem cells for mixed use, thereby exerting the drug effect of treating osteoarthritis.
Description
Technical Field
The disclosure relates to the technical field of biological medicines, in particular to application of an umbilical cord stem cell preparation in preparation of a medicine for treating osteoarthritis.
Background
Arthritis is a chronic arthritic disease with joint degeneration or aging as the pathological basis and joint swelling, pain or dysfunction as the main clinical manifestations, formerly known as osteoarthritis, degenerative osteoarthritis or hypertrophic arthritis, collectively referred to as osteoarthritis. Osteoarthritis is well-developed in the middle aged and elderly, obese patients, sports enthusiasts, or some professional athletes. With the improvement of living conditions and the development of society, the incidence of osteoarthrosis is on the trend of increasing year by year at present. It is known that more than 70% of the elderly are suffering from various joint pains, and osteoarthritis is the most common arthritis, accounting for more than 40% of all arthritis.
The current clinically used medicines can only relieve pain, but the effect is not good. With the continuous development of stem cell research, more therapeutic drugs in the field of osteoarthritis are explored, but the effect is not stable enough. Therefore, there is a need to provide a drug which has a stable effect and can effectively treat osteoarthritis.
Disclosure of Invention
The purpose of the disclosure is to provide an application of an umbilical cord stem cell preparation in preparation of a medicament for treating osteoarthritis, wherein the umbilical cord stem cell can reduce the inflammation level and improve the expression of a chondrocyte marker gene, and the tissue extract, isoliquiritigenin and the umbilical cord stem cell can be mixed for use to effectively improve the repair function of the umbilical cord stem cell, so that the medicament effect of treating osteoarthritis is exerted.
In order to achieve the above objects, the present disclosure provides use of an umbilical cord stem cell preparation for the preparation of a medicament for treating osteoarthritis, the umbilical cord stem cell preparation comprising: umbilical cord mesenchymal stem cells, a tissue extract and isoliquiritigenin.
According to the present disclosure, wherein the concentration of the umbilical cord mesenchymal stem cells is (0.5-5) × 106Per mL;
according to the disclosure, the tissue extract is obtained from Wharton's jelly tissue of umbilical cord, and the molecular weight of the protein in the tissue extract is 3-10KD, and the protein concentration is 0.1-0.8 mg/mL.
According to the disclosure, the concentration of isoliquiritigenin is 0.1-5 mug/mL.
According to the present disclosure, the method for preparing umbilical cord mesenchymal stem cells comprises the following steps: shearing the Wharton's jelly, placing in a serum-free complete culture medium for adherent culture, and discarding the Wharton's jelly fragments for continuous culture when the cell fusion degree is 70-90%; after the culture is finished, digesting and dispersing the centrifugal cells, then centrifuging, inoculating and carrying out subculture to obtain umbilical cord mesenchymal stem cells; preferably, the umbilical cord mesenchymal stem cells are 3-8 generations of cells.
According to the present disclosure, wherein the conditions of adherent culture comprise: the culture time is 14-21 days, and the culture temperature is 37 ℃; completely replacing the primary culture medium in the culture bottle every 3 days on the 7 th to 21 th days of the primary culture;
according to the present disclosure, wherein the conditions of subculture comprise: culturing for 3-5 days at 37 deg.C, and replacing half of subculture medium every 2-3 days.
According to the disclosure, the preparation method of the tissue extracting solution comprises the following steps:
s1, crushing the umbilical cord Wharton' S jelly tissue, centrifuging and taking a tissue supernatant;
s2, adjusting the tissue supernatant to be 0.1-1mg/mL by using physiological saline;
s3, carrying out ultrafiltration treatment on the tissue supernatant with the concentration of 0.1-1mg/mL to obtain a tissue extract.
According to the present disclosure, the crushing process in step S1 includes: the umbilical cord Wharton's jelly tissue is mixed with physiological saline and/or PBS, and then disrupted.
According to the disclosure, the volume ratio of the umbilical cord Wharton's jelly tissue to the physiological saline and/or PBS is 1: (1-5).
The conditions of the centrifugation treatment include: centrifuging for 2-4 times at 3000-10000rpm for 10-30 min; the conditions of the ultrafiltration treatment include: centrifuging for 15-30min at 3000-.
By adopting the technical scheme, the umbilical cord stem cell preparation provided by the disclosure is applied to preparation of a medicament for treating osteoarthritis, wherein the umbilical cord stem cells can obviously reduce inflammatory reaction and improve expression of chondrocyte marker genes, and the tissue extract and the umbilical cord stem cells can be mixed for use to effectively improve the repair function of the umbilical cord stem cells, so that the drug effect of the umbilical cord stem cell preparation for treating osteoarthritis is exerted.
Additional features and advantages of the disclosure will be set forth in the detailed description which follows.
Drawings
The accompanying drawings, which are included to provide a further understanding of the disclosure and are incorporated in and constitute a part of this specification, illustrate embodiments of the disclosure and together with the description serve to explain the disclosure without limiting the disclosure. In the drawings:
FIG. 1 is HE staining results for arthritic pathological injury;
FIG. 2 is the Mankin's score for the extent of arthritis damage;
FIG. 3 shows the expression of chondrocyte marker genes.
Detailed Description
The following describes in detail specific embodiments of the present disclosure. It should be understood that the detailed description and specific examples, while indicating the present disclosure, are given by way of illustration and explanation only, not limitation.
The present disclosure provides an application of an umbilical cord stem cell preparation in the preparation of a medicament for treating osteoarthritis, the umbilical cord stem cell preparation comprises: umbilical cord mesenchymal stem cells, a tissue extract and isoliquiritigenin.
According to the disclosure, the concentration of the umbilical cord mesenchymal stem cells is (0.5-5) x 106one/mL.
According to the disclosure, the tissue extract is obtained from Wharton's jelly tissue of umbilical cord, and the molecular weight of the protein in the tissue extract is 3-10KD, and the protein concentration is 0.1-0.8 mg/mL.
According to the disclosure, the concentration of isoliquiritigenin is 0.1-5 mug/mL.
According to the present disclosure, the method for preparing umbilical cord mesenchymal stem cells comprises the following steps: shearing the Wharton's jelly, placing in a serum-free complete culture medium for adherent culture, and discarding the Wharton's jelly fragments for continuous culture when the cell fusion degree is 70-90%; and after the culture is finished, digesting and dispersing the centrifugal cells, and then centrifuging, inoculating and carrying out subculture to obtain the umbilical cord mesenchymal stem cells.
The umbilical cord mesenchymal stem cells are fibroblast-like cells isolated from umbilical cord tissue, express CD73, CD90, and CD105, and do not express CD14, CD19, CD34, CD45, and HLA-DR.
According to the present disclosure, wherein the conditions of the primary culture comprise: the culture time is 14-21 days, and the culture temperature is 37 ℃; completely replacing the primary culture medium in the culture bottle every 2-3 days on the 7 th-21 th day of primary culture;
according to the present disclosure, wherein the conditions of subculture comprise: culturing for 3-5 days at 37 deg.C, and replacing half of subculture medium every 2-3 days.
According to the disclosure, the preparation method of the tissue extracting solution comprises the following steps:
s1, crushing the umbilical cord Wharton' S jelly tissue, centrifuging and taking a tissue supernatant;
s2, adjusting the tissue supernatant to be 0.1-1mg/mL by using physiological saline;
s3, carrying out ultrafiltration treatment on the tissue supernatant with the concentration of 0.1-1mg/mL to obtain a tissue extract.
Wherein, the conditions of the centrifugal treatment comprise: centrifuging for 2-4 times at 3000-10000rpm for 10-30 min;
the conditions of the ultrafiltration treatment include: centrifuging for 15-30min at 3000-.
According to the present disclosure, the crushing process in step S1 includes: the umbilical cord Wharton's jelly tissue is mixed with physiological saline and/or PBS, and then disrupted.
According to the disclosure, the volume ratio of the umbilical cord Wharton's jelly tissue to the physiological saline and/or PBS is 1: (1-5).
The present disclosure is further illustrated by the following examples, but is not to be construed as being limited thereby.
Serum-free complete media used in the present disclosure are available commercially.
Example 1
Cutting the umbilical cord into 1cm small sections, cleaning the surface by using physiological saline containing double antibodies, and cleaning blood in tissues; after the venous tube and the arterial tube in the tissue are stripped by using sterile forceps, the separated jelly is the Wharton's jelly. 1/3-2/3 of Wharton's jelly was used to isolate umbilical cord stem cells.
Preparing an umbilical cord mesenchymal stem cell preparation UCMSC: suspending umbilical cord mesenchymal stem cells in physiological saline to prepare an umbilical cord stem cell suspension with a total volume of 50 mu L, wherein the concentration of the umbilical cord mesenchymal stem cells is 2 x 106one/mL.
Rat osteoarthritis model construction: injecting 100 mu L of 25mg/mL iodoacetic acid into knee joint cavities of rats by using a syringe to induce early-stage rat knee joint osteoarthritis, and completing model construction after one week.
The umbilical cord mesenchymal stem cell preparation is injected into a rat model side joint once every week for 3 times, sampling is carried out on the 7 th day after the 3 rd injection is completed, knee joint chondrocyte marker genes are detected, meanwhile, joint surface damage pathological conditions are detected through HE staining, and arthritis degree scoring (Mankin's scoring) is carried out, and the result is shown in figures 1-3.
Example 2
The preparation of umbilical cord mesenchymal stem cells and the construction process of rat model of this example are the same as those of example 1.
Preparing a tissue extracting solution: mixing the rest part of the Wharton jelly in the example 1 with the normal saline 1 according to the volume ratio of 1:5, and crushing the tissues by using a tissue homogenizer; centrifuging the crushed tissue at 3000rpm for 10min, collecting supernatant, and repeatedly centrifuging for 3 times under the condition; centrifuging at 10000rpm for 30min, collecting supernatant, and filtering with 0.22 μm filter screen to obtain the final product. Centrifuging the tissue lysate for 20min at 4 deg.C and 4000g with 10KD ultrafilter tube to obtain tissue extract 1 with molecular weight greater than 10 KD; centrifuging the filtrate of the tissue extractive solution 1 with 3KD ultrafilter tube at 4 deg.C and 4000g for 20min to obtain concentrated solution, i.e. protein with molecular weight of 3-10KD, and adjusting protein concentration to 0.5mg/mL with normal saline to obtain tissue extractive solution 2; the final filtrate is protein with molecular weight less than 3KD, and normal saline is used to adjust protein concentration to 0.5mg/mL, namely tissue extract 3.
Preparation of umbilical cord mesenchymal stem cell preparation 1: mixing umbilical cord mesenchymal stem cells, the tissue extracting solution 1 and isoliquiritigenin, adding normal saline for suspension, and preparing an umbilical cord stem cell suspension with a total volume of 50 mu L, wherein the concentration of the umbilical cord mesenchymal stem cells is 2 multiplied by 106The protein concentration is 0.5mg/mL, and the isoliquiritigenin concentration is 2 mug/mL.
Injecting the umbilical cord mesenchymal stem cell preparation 1 into a rat model joint cavity; the injection is performed 3 times once a week, and on the 7 th day after the 3 rd injection is completed, the knee joint chondrocyte marker genes are sampled and detected, meanwhile, the pathological condition of joint surface damage is detected through HE staining, and arthritis degree scoring (Mankin's scoring) is performed, and the results are shown in figures 1-3.
Example 3
The preparation of umbilical cord mesenchymal stem cells and the construction process of a rat model in the embodiment are the same as those in embodiment 1; the umbilical cord tissue extract of this example was prepared in the same manner as in example 2.
Preparation of umbilical cord mesenchymal stem cell preparation 2: mixing umbilical cord mesenchymal stem cells, the tissue extract 2 and isoliquiritigenin, adding normal saline for suspension, and preparing into umbilical cord stem cell suspension with a total volume of 50 μ L, wherein the concentration of umbilical cord mesenchymal stem cells is 2 × 106The protein concentration is 0.5mg/mL, and the isoliquiritigenin concentration is 2 mug/mL.
Injecting the umbilical cord mesenchymal stem cell preparation 2 into a rat model joint cavity once a week for 3 times, sampling and detecting knee joint chondrocyte marker genes on the 7 th day after the 3 rd injection, detecting the pathological condition of joint surface damage by HE staining and scoring the arthritis degree (Mankin's scoring), wherein the results are shown in figures 1-3.
Example 4
The preparation of umbilical cord mesenchymal stem cells and the construction process of a rat model in the embodiment are the same as those in embodiment 1; the umbilical cord tissue extract of this example was prepared in the same manner as in example 2.
Preparation of umbilical cord mesenchymal stem cell preparation 3: mixing umbilical cord mesenchymal stem cells, the tissue extract 3 and isoliquiritigenin, adding normal saline for suspension, and preparing into umbilical cord stem cell suspension with a total volume of 50 μ L, wherein the concentration of umbilical cord mesenchymal stem cells is 2 × 106The protein concentration is 0.5mg/mL, and the isoliquiritigenin concentration is 2 mug/mL.
Injecting the umbilical cord mesenchymal stem cell preparation 3 into a rat model joint cavity once a week for 3 times, sampling and detecting knee joint chondrocyte marker genes on the 7 th day after the 3 rd injection, detecting the pathological condition of joint surface damage by HE staining and scoring the arthritis degree (Mankin's scoring), wherein the results are shown in figures 1-3.
Example 5
The preparation of umbilical cord mesenchymal stem cells and the construction process of a rat model in the embodiment are the same as those in embodiment 1; the umbilical cord tissue extract of this example was prepared in the same manner as in example 2.
Preparation of umbilical cord mesenchymal stem cell preparation 4: mixing umbilical cord mesenchymal stem cells, tissue extract 3 and isoliquiritigenin, adding normal saline to suspend, and preparing into umbilical cord stem cell suspension with total volume of 50 μ L, wherein the concentration of umbilical cord mesenchymal stem cells is 2 × 106The protein concentration is 0.5mg/mL, and the isoliquiritigenin concentration is 10 mug/mL.
Injecting the umbilical cord mesenchymal stem cell preparation 4 into a rat model joint cavity once a week for 3 times, sampling and detecting knee joint chondrocyte marker genes on the 7 th day after the 3 rd injection, detecting the pathological condition of joint surface damage by HE staining and scoring the arthritis degree (Mankin's scoring), wherein the results are shown in figures 1-3.
The model group is an untreated rat model, and as is apparent from fig. 1, joint destruction of the model group is obvious and belongs to symptoms of early arthritis; the damage caused by osteoarthritis can be recovered by different treatment groups, wherein the treatment effect of the preparation 2 group is most obvious;
figure 2 scoring each group according to Mankin's scoring rule, formulation 2 group scored significantly less (× p <0.01) than the other groups, indicating that it was most effective in reducing osteoarticular damage;
in fig. 3, it is shown that the preparation 2 group can promote the expression of the chondrocyte marker genes Aggrecan and Col2a1 to be significantly better than other groups (p < 0.05;. p <0.01), indicating that the protection and the promotion of chondrocyte repair are optimal.
Comparative example 1
This comparative example was prepared in the same manner as in example 2, except that no tissue extract was added to the umbilical cord stem cell preparation in this comparative example. The results show that the umbilical cord stem cell preparation prepared by the comparative example can slightly reduce the bone joint damage and improve the expression of the chondrocyte marker gene.
Comparative example 2
This comparative example was prepared in the same manner as in example 2, except that isoliquiritigenin was not added to the umbilical cord stem cell preparation in this example. The results show that the umbilical cord stem cell preparation prepared by the comparative example can slightly reduce the bone joint damage and improve the expression of the chondrocyte marker gene.
The embodiment shows that the single umbilical cord stem cell can reduce the inflammatory level of osteoarthritis to a certain extent, improve the expression of chondrocyte marker genes and reduce the joint damage degree; the repair function of the umbilical cord stem cells cannot be improved by using the umbilical cord stem cell preparations 1, 3 and 4; the umbilical cord stem cell preparation 2, namely the umbilical cord stem cell mixed tissue extracting solution 2 (tissue extracting solution with molecular weight of 3KD-10 KD) is added with 2 mug/mL isoliquiritigenin, so that the tube arthritis score can be remarkably reduced, inflammation can be reduced, the expression of cartilage cell marker genes can be promoted, and the umbilical cord stem cell preparation 2 prepared by the method can remarkably reduce osteoarthritis damage and protect cartilage cells.
The preferred embodiments of the present disclosure are described in detail with reference to the accompanying drawings, however, the present disclosure is not limited to the specific details of the above embodiments, and various simple modifications may be made to the technical solution of the present disclosure within the technical idea of the present disclosure, and these simple modifications all belong to the protection scope of the present disclosure.
It should be noted that, in the foregoing embodiments, various features described in the above embodiments may be combined in any suitable manner, and in order to avoid unnecessary repetition, various combinations that are possible in the present disclosure are not described again.
In addition, any combination of various embodiments of the present disclosure may be made, and the same should be considered as the disclosure of the present disclosure, as long as it does not depart from the spirit of the present disclosure.
Claims (10)
1. Use of an umbilical cord stem cell preparation in the manufacture of a medicament for the treatment of osteoarthritis, the umbilical cord stem cell preparation comprising: umbilical cord mesenchymal stem cells, a tissue extract and isoliquiritigenin.
2. The use of claim 1, wherein the umbilical cord mesenchymal stem cells are at a concentration of (0.5-5) x 106one/mL.
3. The use according to claim 1, wherein the tissue extract is obtained from Wharton's jelly tissue, and the protein molecular weight of the tissue extract is 3-10KD, and the protein concentration is 0.1-0.8 mg/mL.
4. The use according to claim 1, wherein the concentration of isoliquiritigenin is 0.1-5 μ g/mL.
5. The use according to claim 1, wherein the preparation method of umbilical cord mesenchymal stem cells comprises the following steps: shearing the Wharton's jelly, placing in a serum-free complete culture medium for adherent culture, and discarding the Wharton's jelly fragments for continuous culture when the cell fusion degree is 70-90%; and after the culture is finished, digesting and dispersing the centrifugal cells, and then centrifuging, inoculating and carrying out subculture to obtain the umbilical cord mesenchymal stem cells.
6. The use of claim 5, wherein the conditions of adherent culture comprise: the culture time is 14-21 days, and the culture temperature is 37 ℃; the culture medium in the culture bottle is completely replaced every 2 to 3 days on the 7 th to 21 th days of adherent culture.
7. Use according to claim 5, wherein the conditions of subculture comprise: culturing for 3-5 days at 37 deg.C, and replacing half of subculture medium every 2-3 days.
8. The use according to claim 1, wherein the preparation method of the tissue extract comprises the following steps:
s1, crushing the umbilical cord Wharton' S jelly tissue, centrifuging and taking a tissue supernatant;
s2, adjusting the tissue supernatant to be 0.1-1mg/mL by using physiological saline;
s3, carrying out ultrafiltration treatment on the tissue supernatant with the concentration of 0.1-1mg/mL to obtain a tissue extract.
9. The use of claim 8, wherein the crushing process in step S1 comprises: the umbilical cord Wharton's jelly tissue is mixed with physiological saline and/or PBS, and then disrupted.
10. Use according to claim 9, wherein the volume ratio of umbilical cord Wharton's jelly tissue to physiological saline and/or PBS is 1: (1-5).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111005448.9A CN113662970B (en) | 2021-08-30 | 2021-08-30 | Application of umbilical cord stem cell preparation in preparation of medicines for treating osteoarthritis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111005448.9A CN113662970B (en) | 2021-08-30 | 2021-08-30 | Application of umbilical cord stem cell preparation in preparation of medicines for treating osteoarthritis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113662970A true CN113662970A (en) | 2021-11-19 |
| CN113662970B CN113662970B (en) | 2023-11-24 |
Family
ID=78547376
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111005448.9A Active CN113662970B (en) | 2021-08-30 | 2021-08-30 | Application of umbilical cord stem cell preparation in preparation of medicines for treating osteoarthritis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113662970B (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104651305A (en) * | 2015-02-13 | 2015-05-27 | 沈阳澔源生物科技有限公司 | Method for acquiring bioactive proteins by utilizing umbilical cord mesenchymal stem cells |
| WO2017088829A1 (en) * | 2015-11-27 | 2017-06-01 | 中山大学 | Methods for separating and culturing human testicular mesenchymal stem cells, and use of human testicular mesenchymal stem cells |
| CN108653182A (en) * | 2018-08-06 | 2018-10-16 | 北京贝诗丹生物科技有限公司 | The preparation method and applications of ox umbilical cord active constituent extracting solution |
| CN109675114A (en) * | 2018-12-20 | 2019-04-26 | 康泽生医学生物科技(武汉)有限公司 | A kind of preparation method of people's umbilical cord China Tong Shi glue tissue engineering bracket |
| CN109820869A (en) * | 2019-03-09 | 2019-05-31 | 和携科技(北京)有限公司 | A kind of preparation method of source of people umbilical cord mesenchymal stem cells injection that injecting treatment osteoarthritis for lacuna |
| CN111936174A (en) * | 2018-03-30 | 2020-11-13 | 罗切斯特大学 | Bioengineered Wharton's jelly derived extracellular matrix |
| WO2021085849A1 (en) * | 2019-11-01 | 2021-05-06 | 가톨릭관동대학교산학협력단 | Pharmaceutical composition comprising isoliquiritigenin derivative for prevention or treatment of bone disease |
-
2021
- 2021-08-30 CN CN202111005448.9A patent/CN113662970B/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104651305A (en) * | 2015-02-13 | 2015-05-27 | 沈阳澔源生物科技有限公司 | Method for acquiring bioactive proteins by utilizing umbilical cord mesenchymal stem cells |
| WO2017088829A1 (en) * | 2015-11-27 | 2017-06-01 | 中山大学 | Methods for separating and culturing human testicular mesenchymal stem cells, and use of human testicular mesenchymal stem cells |
| CN111936174A (en) * | 2018-03-30 | 2020-11-13 | 罗切斯特大学 | Bioengineered Wharton's jelly derived extracellular matrix |
| CN108653182A (en) * | 2018-08-06 | 2018-10-16 | 北京贝诗丹生物科技有限公司 | The preparation method and applications of ox umbilical cord active constituent extracting solution |
| CN109675114A (en) * | 2018-12-20 | 2019-04-26 | 康泽生医学生物科技(武汉)有限公司 | A kind of preparation method of people's umbilical cord China Tong Shi glue tissue engineering bracket |
| CN109820869A (en) * | 2019-03-09 | 2019-05-31 | 和携科技(北京)有限公司 | A kind of preparation method of source of people umbilical cord mesenchymal stem cells injection that injecting treatment osteoarthritis for lacuna |
| WO2021085849A1 (en) * | 2019-11-01 | 2021-05-06 | 가톨릭관동대학교산학협력단 | Pharmaceutical composition comprising isoliquiritigenin derivative for prevention or treatment of bone disease |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113662970B (en) | 2023-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6995752B2 (en) | Cell expansion culture method and therapeutic composition | |
| KR101739409B1 (en) | Composition comprising mixture of DNA fragments separated from fish's testis for regenerating cartilage | |
| CN109963574B (en) | Composition for preventing or treating liver fibrosis comprising adipose stem cell-derived exosomes as active ingredient | |
| JP5572777B2 (en) | Cell preparation containing adipocytes | |
| KR101038616B1 (en) | Pharmaceutical composition for use in the treatment, prevention, or allevation of bone and cartilage disease | |
| TWI823964B (en) | Stem cell filtrate preparation and preparation method thereof | |
| KR20210127510A (en) | Compositions for Preventing or Treating Diabetic skin disease Comprising Exosome Derived from Stem Cell Treated with Thrombin | |
| US20170204151A1 (en) | Mesenchymal Stem Cells Expressing Biomarkers that Predict the Effectiveness of Mesenchymal Stem Cells for Treating Diseases and Disorders | |
| KR20200012713A (en) | Pharmaceutical composition for preventing or treating acute liver diseases comprising an exosome as an active ingredient | |
| CN107551095B (en) | A skin repairing agent for psoriasis prepared from stem cell extract and Chinese medicinal extract | |
| CN106062184A (en) | Odontogenic stem cells and use of genetically modified odontogenic stem cells | |
| KR102155141B1 (en) | A Atopy Treating Scrab Washer Using A Stem Cell Crushed Extract(Free-Membrane Stem Cell) and A Coffee Beans Crushed Powder | |
| CN113662970B (en) | Application of umbilical cord stem cell preparation in preparation of medicines for treating osteoarthritis | |
| CN110731969A (en) | Preparation of mesenchymal stem cells and application of mesenchymal stem cells in preparation of pain medicines | |
| Luo et al. | Mesenchymal stem cell-derived exosomes as a promising cell-free therapy for knee osteoarthritis | |
| KR101407611B1 (en) | Dioscoreae Rhizoma comprising the manufacture of a medicament for the treatment of facial nerve paralysis, and the extract beongbeop | |
| Tremolada et al. | Mesenchymal Stromal Cells and Micro Fragmented Adipose Tissue: New Horizons of Effectiveness of Lipogems. J | |
| CN108392624B (en) | Activity promoting peptide and application of mesenchymal stem cells in treating rheumatoid arthritis | |
| CN110742906A (en) | Application of mesenchymal stem cell paracrine factor in preparation of pain medicine | |
| US20200155608A1 (en) | Therapeutic Treatments Via Intravenous Infusion Of Mesenchymal Stem Cells | |
| EP2952199B1 (en) | Use of allogeneic interstitial vessel-layer cell and allogeneic mesenchymal progenitor cell for preventing or treating osteoarthritis | |
| CN108126187A (en) | A kind of composition and preparation method | |
| CN116059246A (en) | Application and preparation of MSCs and AMP in preparation of product for intervening in atopic dermatitis | |
| CN107595886B (en) | Preparation method for reconstructing mouse model of Kupffer cells in liver | |
| CN117414365A (en) | Application of ketoconazole in preparation of medicine for treating degenerative osteoarthritis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |